Bispecific Antibodies & T-Cell Engagers: A Breakthrough in Cancer Immunotherapy

Bispecific Antibodies & T-Cell Engagers: A Breakthrough in Cancer Immunotherapy

Bispecific antibodies transform cancer treatment.

They bind two different targets at once. One arm grabs a tumour cell antigen. The other arm latches onto a T cell. So, they bring killer T cells right next to cancer cells.

T-cell engagers form a major subset. They redirect the patient’s own immune cells. This creates a powerful bridge between immune system and tumour.

Blincyto (blinatumomab) leads the way. It targets CD19 on B-cell cancers. At the same time, it engages CD3 on T cells. This forces T cells to attack leukemia and lymphoma cells directly.

Teclistamab targets BCMA on multiple myeloma cells. It also hooks CD3 on T cells. Patients see deep responses even in relapsed cases.

Mosunetuzumab works similarly. It hits CD20 on B cells. Then it recruits T cells to destroy follicular lymphoma.

These drugs activate T cells strongly. They trigger cytokine release. Therefore, doctors monitor cytokine release syndrome (CRS) carefully.

Neurological side effects appear sometimes. ICANS (immune effector cell-associated neurotoxicity syndrome) requires prompt management.

Administration stays simple. Many bispecifics use subcutaneous injection. Others need short hospital infusions.

Combination therapies gain momentum. Researchers pair them with checkpoint inhibitors. They also test them with CAR-T or chemotherapy.

New designs improve safety. Some use conditional activation. Others switch formats to reduce off-target effects.

Bispecific antibodies expand rapidly. Over 100 candidates enter clinical trials now. Solid tumours become the next big frontier.

T-cell engagers offer hope for hard-to-treat cancers. They harness the immune system naturally. So, patients achieve durable remissions more often.

The field moves fast. More approvals arrive every year.